GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Cathay Biotech Inc (SHSE:688065) » Definitions » EBIT

Cathay Biotech (SHSE:688065) EBIT : ¥529 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cathay Biotech EBIT?

Cathay Biotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥134 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥529 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cathay Biotech's annualized ROC % for the quarter that ended in Mar. 2024 was 2.62%. Cathay Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cathay Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2.15%.


Cathay Biotech EBIT Historical Data

The historical data trend for Cathay Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cathay Biotech EBIT Chart

Cathay Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 572.90 524.65 740.74 716.00 481.10

Cathay Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.47 225.83 104.05 65.75 133.72

Competitive Comparison of Cathay Biotech's EBIT

For the Chemicals subindustry, Cathay Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cathay Biotech's EV-to-EBIT Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Cathay Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cathay Biotech's EV-to-EBIT falls into.



Cathay Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥529 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cathay Biotech  (SHSE:688065) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cathay Biotech's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=385.18 * ( 1 - 13.68% )/( (12809.667 + 12584.117)/ 2 )
=332.487376/12696.892
=2.62 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18833.373 - 1862.791 - ( 5390.687 - max(0, 3409.753 - 7570.668+5390.687))
=12809.667

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18617.744 - 1635.808 - ( 4988.231 - max(0, 2753.664 - 7151.483+4988.231))
=12584.117

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cathay Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=534.896/( ( (9375.786 + max(148.23, 0)) + (9541.645 + max(346.445, 0)) )/ 2 )
=534.896/( ( 9524.016 + 9888.09 )/ 2 )
=534.896/9706.053
=5.51 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(243.256 + 1466.356 + 317.748) - (1862.791 + 0 + 16.339)
=148.23

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(291.69 + 1374.593 + 348.556) - (1635.808 + 0 + 32.586)
=346.445

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cathay Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=529.351/24661.770
=2.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cathay Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Cathay Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cathay Biotech (SHSE:688065) Business Description

Traded in Other Exchanges
N/A
Address
1690 Cailun Road, 4th Floor, Building 5, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Cathay Biotech Inc is engaged in production of revolutionary products, including bio-based polyamide,bio-based DN5 (1,5-pentanediamine), long chain dibasic acids (LCDA) and biobutanol. The company's commercial development platform focuses on research of molecular biology, fermentation process engineering, polymer material. Its products include Dibasic Acids, Pentamethylene Diamine, and Bio-based Polyamide.

Cathay Biotech (SHSE:688065) Headlines

No Headlines